Blog – Katalyst Wealth

[Stock idea]: Faze 3 – ₹950 Cr revenue, 55% capacity utilization — the math here is interesting

August 18, 2026

Most companies chase customers. This one has customers asking for 10x their current order volumes — and it still can’t fully use the factories it already built. We dug into the latest investor presentation of Faze Three Limited, a Silvassa-based home & technical textiles exporter, and a few numbers stood out enough to share with our free readers. Spread the Word: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word…

[Stock idea]: NRB Bearings – From a factory fire to a ₹2,500 cr roadmap: NRB Bearings’ Q4

July 30, 2026

NRB Bearings just posted a 77% jump in full-year PAT — but the real story is what happened before this year, not during it. A factory fire, a family settlement, and a demerger all hit this company in the last three years. Q4 FY26 is the quarter management says draws a line under all three. Here’s what stood out, but before that: Spread the Word: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you…

[Stock idea]: ₹372 cr → ₹1,000 cr: the 3-year roadmap this ₹2,700 cr company just laid out

July 28, 2026

Sirca Paints India just closed out FY26 with its strongest year yet — but the more interesting story is buried in the concall, not the press release. Revenue crossed ₹492 crore, EBITDA margins expanded even as crude-linked raw material costs spiked, and management just laid out a very specific path to ₹1,000 crore by FY29. Here’s what stood out, but before that: Spread the Word: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d…

[Stock idea]: Windlas Biotech — 13 quarters in a row of record growth

July 23, 2026

While most of the market was distracted by largecap pharma names, a smaller CDMO player quietly delivered its 13th consecutive quarter of record revenue. No new drug launch. No big acquisition. Just consistent execution, disciplined capital allocation, and margins that keep inching up. Here’s what caught our eye, but before that: Help us grow: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word about Katalyst Wealth. Latest Stock recommendations…